Free Trial
NASDAQ:GRI

GRI Bio (GRI) Stock Price, News & Analysis

GRI Bio logo
$1.37 +0.02 (+1.48%)
As of 04:00 PM Eastern

About GRI Bio Stock (NASDAQ:GRI)

Key Stats

Today's Range
$1.29
$1.40
50-Day Range
$1.20
$8.06
52-Week Range
$1.10
$81.77
Volume
109,777 shs
Average Volume
309,414 shs
Market Capitalization
$2.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
Consensus Rating
Buy

Company Overview

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

GRI MarketRank™: 

GRI Bio scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GRI Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GRI Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about GRI Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for GRI Bio are expected to grow in the coming year, from ($3.04) to ($0.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GRI Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GRI Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GRI Bio has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about GRI Bio's valuation and earnings.
  • Percentage of Shares Shorted

    2.78% of the float of GRI Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    GRI Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GRI Bio has recently decreased by 37.81%, indicating that investor sentiment is improving significantly.
  • Percentage of Shares Shorted

    2.78% of the float of GRI Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    GRI Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GRI Bio has recently decreased by 37.81%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    GRI Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for GRI Bio this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added GRI Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GRI Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of GRI Bio is held by insiders.

  • Percentage Held by Institutions

    Only 33.95% of the stock of GRI Bio is held by institutions.

  • Read more about GRI Bio's insider trading history.
Receive GRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter.

GRI Stock News Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
GRI Bio (NASDAQ:GRI) Trading Down 4% - Here's Why
GRI Bio Expands Share Offering Agreement
See More Headlines

GRI Stock Analysis - Frequently Asked Questions

GRI Bio's stock was trading at $14.0828 at the beginning of 2025. Since then, GRI stock has decreased by 90.3% and is now trading at $1.37.
View the best growth stocks for 2025 here
.

GRI Bio, Inc. (NASDAQ:GRI) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($5.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.08) by $1.72.

GRI Bio shares reverse split on Monday, February 24th 2025. The 1-17 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GRI Bio investors own include SoFi Technologies (SOFI), NuCana (NCNA), Caribou Biosciences (CRBU), Cardio Diagnostics (CDIO), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

Last Earnings
5/15/2025
Today
5/29/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRI
Fax
N/A
Employees
1
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$34.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,529.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.04 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.22 per share
Price / Book
0.26

Miscellaneous

Free Float
8,921,000
Market Cap
$2.89 million
Optionable
Not Optionable
Beta
-1.67
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:GRI) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners